Navigation Links
Stem cells may be key to understanding the origins of colon cancer and detecting relapse
Date:3/17/2011

Colorectal cancer cells trigger a set of genes similar to those found in intestinal stem cells, scientists at the Institute for Research in Biomedicine (IRB Barcelona) have found. The team of researchers, led by ICREA researcher Eduard Batlle, propose that patients with colorectal cancer undergo genetic tests of their intestinal epithelium in order to predict a higher risk of relapse. The results of the study, published online this week in Cell Stem Cell, offer new possibilities for diagnosing and treating the disease.

Colon cancer is the second cause of death by cancer worldwide. Current treatment for the disease normally involves a combination of surgery and chemotherapy. Most patients who are treated successfully go into remission, but nearly 40% relapse within months or years, when the cancer returns or metastasizes. "This shows us that there are cells within the tumour that regenerate the disease," says Batlle, "but we still know very little about the biological reasons why."

Cancer's "hard core"

The study conducted by Anna Merlos-Surez and other researchers in Batlle's team has uncovered a close relation between intestinal stem cells (non-specialised cells that generate all cells within the intestine) and colorectal cancer. The researchers compared genes that are activated in cells from a healthy intestine both stem cells and specialised cells with the genes that are activated in tumour cells taken from patients. "Our results show that patients with colon cancer have a set of genes activated that is very similar to the set activated in stem cells. The more genes they have activated in common, the more likely it is that the patient's cancer will spread and relapse.

These stem cell genes become activated in a subset of cells in the tumour, called "tumour stem cells". When Batlle's team transplanted these cells into mice, tumours formed. Their results add to the growing hypothesis that cancer organizes itself hierarchically, in such a way that only specific cells, "tumour stem cells", are able to initiate and propagate the cancer.

What is it about stem cells that allows them to promote cancer? By definition, stem cells renew tissues, including in this case the intestinal epithelium, and can produce up to 5 grams of intestinal epithelial cells each day. Scientists believe that tumours may exploit the capacity of these cells to renew indefinitely in order to grow and spread. Furthermore, while the majority of cells have an average lifespan of days, as in the case of intestinal epithelial cells, or even months, stem cells survive for many years, increasing the probability that their DNA will accumulate damage and that they will turn cancerous.

One of the biggest hurdles that oncologists face is a lack of tools to identify which patients have a higher risk of relapse. Discovering a close relation between intestinal stem cells and the propagation of cancer is a clear breakthrough in this respect. The hypothesis that colorectal cancer requires a specific type of cell to develop and thrive has also been demonstrated in other types of cancer, including gliomas, some types of lymphoma or breast cancer. This finding opens the door for the development of treaments aimed at these new targets in the fight against cancer: tumour stem cells.


'/>"/>

Contact: Nuria Noriega
nuria.noriega@irbbarcelona.org
Institute for Research in Biomedicine (IRB Barcelona)
Source:Eurekalert

Related biology news :

1. Johns Hopkins team creates stem cells from schizophrenia patients
2. Laser beam makes cells breathe in water and potentially anti-cancer drugs
3. Method reveals new view of human nerve cells, opening door to potential drug targets
4. Rensselaer professor utilizing New York state grant to study adult stem cells
5. 3-D tracking of single molecules inside cells
6. Columbia engineer observes surprising behavior of cells during blood-vessel formation
7. Rockefeller Scientists discover new compound that rids cells of Alzheimer protein debris
8. A new stem cell enters the mix: Induced conditional self-renewing progenitor cells
9. Scripps Research scientists develop new test for pluripotent stem cells
10. Jekyll and Hyde: Cells executioner can also stave off death
11. A little off the top helps NIST map cells with submicrometer resolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: